Tocilizumab as Add-On Treatment For Residual Positive, Negative, and Cognitive Symptoms of Schizophrenia

NCT02034474 · clinicaltrials.gov ↗

PHASE4

Phase

COMPLETED

Status

59

Enrollment

OTHER

Sponsor class

Conditions

Schizophrenia
Schizoaffective Disorder

Interventions

DRUG: Tocilizumab
DRUG: Placebo

Sponsor

New York State Psychiatric Institute

Collaborators

[object Object]